With 65% Institutional Ownership, Teva Pharmaceutical Industries Limited (NYSE:TEVA) Is a Favorite Amongst the Big Guns
With 65% Institutional Ownership, Teva Pharmaceutical Industries Limited (NYSE:TEVA) Is a Favorite Amongst the Big Guns
Key Insights
主要見解
- Given the large stake in the stock by institutions, Teva Pharmaceutical Industries' stock price might be vulnerable to their trading decisions
- 45% of the business is held by the top 25 shareholders
- Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
- 考慮到機構在該股票中擁有的大量股份,梯瓦製藥股價可能容易受機構的交易決策的影響。
- 前25大股東佔45%的業務。
- 分析師預測以及所有者數據可以給我們提供有關業務前景的強烈想法。
A look at the shareholders of Teva Pharmaceutical Industries Limited (NYSE:TEVA) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 65% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
紐交所:TEVA所有基金類型都持有一大部分股份,機構是該公司的着重點,佔有65%的股份。換句話說,機構面臨着最大的上漲潛力(或下行風險)。
Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.
由於他們擁有的巨額資金和研究能力,機構所有權往往具有很大的影響力,特別是對於個人投資者來說。因此,擁有大量機構資金投資於公司往往被認爲是一種令人嚮往的品質。
In the chart below, we zoom in on the different ownership groups of Teva Pharmaceutical Industries.
下面的圖表是對梯瓦製藥持股人的不同所有權群體進行了放大。
![ownership-breakdown](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240621/0-bd0bef4f200e8724b78e85060077469f-0-5921334835e95ad00f1f247715ba1b7a.png/big)
What Does The Institutional Ownership Tell Us About Teva Pharmaceutical Industries?
機構所有權對梯瓦製藥有何影響?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。
Teva Pharmaceutical Industries already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Teva Pharmaceutical Industries' earnings history below. Of course, the future is what really matters.
梯瓦製藥已經有機構在股權登記簿上了。事實上,他們在公司中擁有可觀的股份。這表明,機構在專業投資者中具有一定的信譽度。但我們不能僅僅依賴這個事實,因爲機構有時也會做出糟糕的投資,就像普通人一樣。如果多個機構同時改變他們對某一隻股票的看法,你可能會看到股價快速下跌。因此,值得查看一下梯瓦製藥的營業收入歷史記錄。當然,未來才是真正重要的。
![earnings-and-revenue-growth](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240621/0-bd0bef4f200e8724b78e85060077469f-1-176c78074d096db4247bb022d0dcbc05.png/big)
Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Teva Pharmaceutical Industries. The company's largest shareholder is Phoenix Investments & Finances Ltd, with ownership of 4.8%. For context, the second largest shareholder holds about 3.9% of the shares outstanding, followed by an ownership of 3.7% by the third-largest shareholder.
投資者應該注意,機構實際上擁有超過一半的公司股份,因此他們可以共同行使重大權力。對於梯瓦製藥,對沖基金的持股很少。該公司最大的股東是Phoenix Investments & Finances Ltd,擁有4.8%的股份。爲了更好地理解,第二大股東持有約3.9%的流通股,第三大股東持有3.7%的流通股。
On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.
經過我們的所有權數據研究,我們發現前25位股東共同擁有不到50%的股份,表明沒有任何個人擁有多數利益。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
儘管研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議也是一個好習慣,以深入了解股票的預期表現。有許多分析師對這支股票進行了覆蓋,因此了解他們的預測可能值得一試。
Insider Ownership Of Teva Pharmaceutical Industries
梯瓦製藥的內部股權情況。
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
雖然“內部人士”的明確定義具有主觀性,但幾乎所有人都認爲董事會成員是內部人士。公司管理業務,但首席執行官即使是董事會成員,也要向董事會負責。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。
Our data suggests that insiders own under 1% of Teva Pharmaceutical Industries Limited in their own names. As it is a large company, we'd only expect insiders to own a small percentage of it. But it's worth noting that they own US$116m worth of shares. It is good to see board members owning shares, but it might be worth checking if those insiders have been buying.
我們的數據表明,內部人員在自己的名字下僅擁有梯瓦製藥的不到1%的股份。由於它是一家大型公司,我們只希望內部人員擁有其中的一小部分。但值得注意的是,他們擁有1.16億美元的股份。看到董事會成員擁有股份是好的,但如果那些內部人員一直在購買,那麼這可能值得注意。
General Public Ownership
一般大衆所有權
The general public-- including retail investors -- own 34% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
重要的是要考慮到不同的分組擁有某家公司的股份。但是爲了更好地了解瑞建,我們需要考慮許多其他因素。例如,不斷存在的投資風險。我們已經確定了瑞建的2個警告信號,並且了解它們應該成爲您的投資過程的一部分。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Teva Pharmaceutical Industries better, we need to consider many other factors.
總之,想要了解梯瓦製藥,我們需要考慮許多其他因素,而不僅僅是不同的持股人群體。
I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.
我喜歡更深入地了解公司過去的表現。您可以在以下詳細圖表中找到歷史收益和收入。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。